Registry update — unassessed
Effect of Mammalian Target of Rapamycin Inhibition and Other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Functional Consequences
Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 4, 2018 · Discovered: Sep 19, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract provides no efficacy or safety results from the human trial, only study rationale and design
- Preclinical benefits in mice do not establish that rapamycin produces similar effects in elderly humans
- Without reported outcomes, this abstract alone cannot demonstrate whether rapamycin improves immune response, cognition, or function in the target population
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Elderly persons aged 70-95
- Primary outcome
- Improvement in life functions; effects on immune responsiveness, cognitive function, and functional consequences
- Effect size
- —
- Significance
- Not reported
- Journal
- The University of Texas Health Science Center at San Antonio
- Published
- Dec 4, 2018
Sources
Primary source
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Investigators are conducting a translational trial to test whether rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95)
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.